## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.63 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (52% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($92.01)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 2, Bearish: 1)

**1. Revvity Inc.: Quiet Re?Rating Story in a Volatile Diagnostics Market**
- Source: AD HOC NEWS | 20251230T140835 | Bullish | Relevance: 100%
- Revvity Inc., a life-sciences and diagnostics company, is undergoing a quiet rerating as it reinvents itself post-PerkinElmer divestiture. The company has been tightening its portfolio, integrating acquisitions, and focusing on genomics, diagnostics, and analytical technologies. Investors are slowly becoming more constructive, with the stock showing a gradual uptrend driven by improved earnings visibility and strategic reset.

**2. Hereâ€™s Why Diamond Hill Mid Cap Composite Purchased Revvity (RVTY) in Q3**
- Source: Insider Monkey | 20251231T124735 | Somewhat-Bullish | Relevance: 100%
- Diamond Hill Mid Cap Strategy acquired shares of Revvity, Inc. (NYSE: RVTY) in Q3 2025 finding its price undervalued compared to its long-term growth outlook. Revvity, a life sciences tools and diagnostics company, has upgraded its product portfolio to higher-margin offerings. Despite market rallies, Diamond Hill capitalized on investor concerns about biopharmaceutical policy uncertainty to add Revvity at a discount to its intrinsic value estimate.

**3. Revvity Inc.: Quiet Re?Rating Story in a Volatile Diagnostics Market**
- Source: AD HOC NEWS | 20251230T141625 | Bullish | Relevance: 100%
- Revvity Inc. is undergoing a quiet but significant rerating in the volatile life-sciences and diagnostics market. The company, which emerged from PerkinElmer's divestiture, has focused on tightening its portfolio and convincing investors of a deserving higher multiple for its genomics, diagnostics, and analytical technologies. Wall Street sentiment is shifting from cautious neutrality to constructive endorsement, with analysts seeing the company as undervalued given its strategic reset and focus on recurring revenue streams.

**4. Revvity, Inc. Faces Valuation Shift Amid Declining Sales and Rising Costs**
- Source: Markets Mojo | 20251230T115933 | Bearish | Relevance: 100%
- Revvity, Inc., a small-cap Pharmaceuticals & Biotechnology company, has experienced a shift in its valuation grade from attractive to very expensive. This change is attributed to declining net sales and operating profit over the past five years, alongside rising raw material costs and a high debt-equity ratio. The company's financial metrics, including a P/E ratio of 33 and a modest dividend yield of 0.32%, reflect these challenges.

**5. Revvity Inc. Stock Finds Its Footing as Investors Weigh Diagnostics Demand and AI Ambitions**
- Source: AD HOC NEWS | 20251230T001052 | Somewhat-Bullish | Relevance: 100%
- Revvity Inc. shares have found a cautious equilibrium after a volatile year, with investors re-evaluating the company's post-spin-off strategy, AI-enabled lab tools, and varying demand in life sciences. The stock has underperformed broader market benchmarks over the past year but analysts remain cautiously constructive, seeing mid-teens upside potential. Revvity's future growth hinges on its transformation into a data-driven partner, expanding its diagnostics footprint, deepening life sciences tools, and integrating digital and analytical capabilities.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 18.2x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.2B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 18.2 |
| Current P/E | 19.7 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.5% to -1.6% (+2.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.6pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.7%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). RSI neutral at 46. Volume at 52% of 20MA suggests lack of conviction. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.59% (CS: 27) | Neutral |
| RSI_14 | 46.2 | Neutral |
| MACD Histogram | -0.43 | Bearish |
| vs SMA20 | 0.978x | Below |
| vs SMA50 | 0.997x | Below |
| vs SMA200 | 1.025x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $96.75
- **Stop Loss:** $92.01 (4.9% risk)
- **Target:** $106.23 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 303
- **Position Value:** $29,315.25
- **Portfolio %:** 29.32%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*